Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.87B 1.61B 1.51B 1.38B 2.6B 179B 2.61B 17.84B 6.91B 90.06B 7.03B 6.87B 298B P/E 2026 *
-3.98x
P/E 2027 * -4.06x
Enterprise Value 1.48B 1.27B 1.2B 1.09B 2.06B 142B 2.07B 14.15B 5.48B 71.41B 5.57B 5.45B 237B EV / Sales 2026 *
34.8x
EV / Sales 2027 * 29.2x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week-0.29%
Current month+16.33%
1 month+17.91%
3 months+17.51%
6 months-7.43%
Current year-14.67%
1 week 3.22
Extreme 3.215
3.63
1 month 2.86
Extreme 2.86
3.63
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
29.4
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer 57 06/04/2026
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap.
8/17/26 A Tax

Chief Technology Officer

-26,657 0.0051%
8/17/26 A Tax

Chief Executive Officer

-80,498 0.0153%
8/17/26 A Tax

Chief Financial Officer

-25,018 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-0.29%-27.74%-59.09% 1.87B
+3.31%-3.70%+61.03%+103.64% 70.42B
+2.09%+2.28%+49.95%+91.30% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-0.49%+1.53%+58.69%+11.38% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
-1.68%+0.33%+36.86%-16.09% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+2.50%+0.09%+15.13%+554.60% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.56%+1.01%+51.12%+172.65% 29.02B
Weighted average by Cap. +1.17%+0.71%+56.17%+156.44%

Financials

2026 *2027 *
Net sales 42.68M 36.63M 34.39M 31.41M 59.27M 4.07B 59.56M 407M 158M 2.05B 160M 157M 6.8B 56.25M 48.28M 45.32M 41.39M 78.11M 5.37B 78.49M 536M 208M 2.71B 211M 207M 8.96B
Net income -459M -394M -370M -338M -637M -43.76B -640M -4.37B -1.69B -22.07B -1.72B -1.69B -73.11B -474M -407M -382M -349M -659M -45.24B -662M -4.52B -1.75B -22.83B -1.78B -1.74B -75.6B
Net Debt -388M -333M -312M -285M -538M -36.96B -541M -3.69B -1.43B -18.65B -1.45B -1.42B -61.76B -227M -195M -183M -167M -315M -21.62B -316M -2.16B -838M -10.91B -851M -833M -36.13B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26/08/26 $3.490 -1.97% 12,978,424
25/08/26 $3.560 +9.54% 22,516,735
24/08/26 $3.250 -7.14% 15,155,115
21/08/26 $3.500 +4.79% 22,898,467
20/08/26 $3.340 -4.57% 21,453,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.490USD
Average target price
7.217USD
Spread / Average Target
+106.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock